NASDAQ: TRMLTourmaline Bio Inc Stock
$47.98+0.02 (+0.04%)
Updated Oct 24, 2025
TRML Price
$47.98
Fair Value Price
$1.19
Market Cap
$1.23B
52 Week Low
$11.56
52 Week High
$48.27
P/E
-13.95x
P/B
4.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$88.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$86M
Beta
1.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TRML Overview
Talaris Therapeutics Incorporated is a late-clinical stage cell therapy company in the U.S. The company is developing a allogeneic, hematopoietic stem cell transplantation method which, if it succeeds, will transform the standard of care for solid organ transplantation and severe autoimmune diseases, as well as for severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, in a Phase II trial for living donor kidney transplant patients. Talaris was founded in 1988 and is headquartered in Louisville, KY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRML's potential to beat the market
- TRML doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TRML
RankedUnranked of 486
RankedUnranked of 486
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.28 | A | |
| $11.89 | A | |
| $7.20 | A |
Be the first to know about important TRML news, forecast changes, insider trades & much more!
TRML News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRML scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRML ($47.98) is overvalued by 3,918.89% relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TRML ($47.98) is not significantly undervalued (3,918.89%) relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TRML is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TRML due diligence checks available for Premium users.
Valuation
TRML fair value
Fair Value of TRML stock based on Discounted Cash Flow (DCF)
Price
$47.98
Fair Value
$1.19
Overvalued by
3,918.89%
TRML ($47.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRML ($47.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRML is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TRML price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.95x
Industry
-88.22x
Market
38.93x
TRML price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.76x
Industry
4.92x
TRML is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRML's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.1M
Profit Margin
0%
TRML's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$269.3M
Liabilities
$10.1M
Debt to equity
0.04
TRML's short-term assets ($249.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRML's short-term assets ($249.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRML's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.3M
Investing
$16.3M
Financing
$54.0k
TRML's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRML vs Biotech Stocks
Tourmaline Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.